news
Charles River Laboratories announces new tumour model compendium
The Compendium provides scientists an online resource to help design efficient in vitro and in vivo oncology research studies.
List view / Grid view
Immuno-oncology
news
Local environment plays key role in breast cancer progression
While studying the complex correlation between tissue stiffness and breast cancer development, researchers found that cancer cells tend to become more aggressive when the surrounding tissue stiffens...
news
Immune signature predicts asthma susceptibility
Researchers have identified a subset of T cells, whose frequency serves as early childhood immune signature that predicts the risk of developing asthma later on.
webinar
Streamlining drug discovery assays for cancer and cardiovascular disease
1 February 2018 | By PerkinElmer
This webinar discussed a screening assay that recapitulates the activation of ER stress sensor IRE1 and an assay to quantify cell migration phenotypes, as applied to cardiovascular target validation and drug discovery.
news
Stealth virus for cancer therapy
Scientists have rebuilt adenoviruses so that they effectively recognise and infect tumour cells.
news
Study suggests PD-1 inhibitors against aggressive pediatric brain cancer subtype
A study has laid the groundwork for the use of PD-1 inhibitors with an aggressive form of brain cancer, namely supratentorial pediatric ependymoma.
news
Immune cells dictate tumour progression
Analysing individuals' genotypes and immunotypes could yield customised treatments for prostate cancer...
news
Researchers use AI technology to chart immune cell receptor
Johns Hopkins scientists have used a form of artificial intelligence to create a map that compares types of cellular receptors, the chemical ‘antennas’ on the surface of immune system T-cells.
webinar
High throughput flow cytometry for multifactorial evaluation of novel therapeutic candidates using an innovative In vitro immuno-oncology screening platform
4 January 2018 | By IntelliCyt Corporation
In this webinar, speakers discussed how the IntelliCyt iQue Screener Plus platform is being utilised to deliver rich datasets for compound screening, target validation and is how it is transforming immuno-oncology.
article
Expert view: Addressing the big challenges in drug screening
One of the biggest challenges facing drug discovery across all therapeutic modalities (small molecule, biologics, and cellular) remains the balance between physiological relevance and throughput.
news
Novel compound restores immune response in patients with melanoma
A novel compound may restore immune response in patients with melanoma, according to a study presented at the ESMO Immuno Oncology Congress 2017.1
news
BTSA1 causes cancer to self-destruct without affecting healthy cells
Scientists have discovered a compound that causes cancer cells to self-destruct while sparing healthy cells...
webinar
Advancing the discovery of immunotherapeutics with large scale multiplexed experiments
27 September 2017 | By IntelliCyt Corporation
In this webinar, Belen Ybarrondo, Ph.D and Thomas Duensing, Ph.D discuss the challenges faced with antibody screening and how the iQue Screener can give an evaluation of cell killing mechanism, screening for immune checkpoint inhibitors and more...
webinar
Evaluating immunotherapeutic approaches with large scale functional assays for immuno-oncology
22 September 2017 | By IntelliCyt Corporation
In this webinar, Belen Ybarrondo, Ph.D and Thomas Duensing, Ph.D discuss the need for robust high content tools for current immunotherapeutic approaches, and how IntelliCyt's iQue Screener PLUS can give functional efficacy of immuno-oncology therapies...
news
Avenue discovered for precision cancer treatment
A novel chemical dubbed "T-REX," along with a patent-pending targeting molecule have uncovered interesting facets of several well-known cancer-cell mutations that, if present in a patient, could inform treatment options and potentially produce more favourable outcomes...
